Trump’s Unconventional Strategy to Tackle U.S. Drug Price Hikes

Man in a suit waving against dark background.

President Donald Trump plans to slash U.S. prescription drug prices by 30-80% through an executive order that would force pharmaceutical companies to match the lowest international prices, sending shockwaves through global pharma markets.

Key Takeaways

Trump will sign an executive order implementing a “Most Favored Nation’s Policy” to align U.S. drug prices with the lowest prices available internationally
The policy aims to end the practice of Americans subsidizing drug costs for the rest of the world, potentially saving “trillions of dollars”
Billionaire investor Bill Ackman praised Trump as the “first president in history to rectify the situation” of unfair drug pricing
Pharmaceutical stocks globally tumbled following Trump’s announcement, with significant declines across Europe, Asia, and India
The U.S. national debt has reached $37 trillion, with Ackman criticizing subsidies as a contributing factor

Trump’s Bold Plan to Slash American Drug Prices

President Donald Trump has announced plans to sign an executive order on May 12 that would dramatically reduce prescription drug prices in the United States by implementing a “Most Favored Nation’s Policy.” This policy would require pharmaceutical companies to sell drugs to Americans at the same prices they offer to other countries, potentially cutting costs by 30% to 80%. The move directly addresses a longstanding problem where American consumers often pay many times more for medications than patients in other developed nations for identical products.

Trump’s announcement sent pharmaceutical stocks tumbling globally, with significant declines observed across markets in Europe, Asia, and India. The policy represents a direct challenge to the pharmaceutical industry’s pricing model that has long forced Americans to shoulder disproportionately high costs for medications. Industry analysts suggest this could fundamentally reshape how drug pricing works globally, as companies would need to establish more uniform international pricing or potentially lose access to the lucrative American market.

Ackman’s Influence and Support

Billionaire investor Bill Ackman, CEO of Pershing Square Capital Management, has emerged as a vocal supporter of Trump’s drug pricing initiative. Ackman previously suggested making it illegal for pharmaceutical companies to sell drugs abroad at lower prices than in the U.S., a concept Trump appears to have adopted. The hedge fund manager praised Trump’s executive order on social media, suggesting the President “must have liked my idea” and lauding him as the first president to take concrete action on the issue.

“President Donald Trump must have liked my idea. He is the first president in history to rectify the situation where Americans subsidize the cost of drugs for the rest of the world,” Ackman stated.

Ackman has consistently criticized various subsidies for contributing to the ballooning national debt, which has reached a staggering $37 trillion. His support for Trump’s policy stems from his belief that ending the effective subsidy of global drug costs by American consumers represents a crucial step toward fiscal responsibility while also delivering tangible benefits to American patients struggling with medication costs.

Market Impact and Economic Implications

The announcement has already triggered significant market reactions, with pharmaceutical companies facing investor concerns about potential revenue impacts. The SPDR S&P 500 ETF Trust and Invesco QQQ Trust ETF both experienced slight declines following the news, though broader market futures showed resilience. For everyday Americans, the policy could translate to substantial savings on prescription medications that have long strained household budgets, particularly for seniors and those with chronic conditions requiring ongoing treatment.

“The best way to reduce drug prices in the US is to make it illegal for drug companies to sell the same drugs abroad for lower prices than they sell them for here. This will force a globally negotiated price that will be lower than the prices that US consumers pay now and higher than what foreigners pay now. Otherwise we are stuck with a system where American consumers subsidize drug development for the rest of the world.” Ackman expressed.

Trump has claimed the policy could save Americans “trillions of dollars” over time while bringing fundamental fairness to a system that has disadvantaged U.S. consumers for decades. Critics of the pharmaceutical industry have long questioned why identical medications manufactured in the same facilities cost substantially more in America than in countries like Canada, Japan, or European nations. Trump’s executive order directly challenges this pricing disparity in a way previous administrations have avoided.

A New Era for American Drug Pricing

If implemented as described, Trump’s executive order would represent one of the most significant healthcare policy changes in recent history. By leveraging the purchasing power of the world’s largest pharmaceutical market, the policy aims to force global price equalization that benefits American consumers who have effectively subsidized lower drug prices abroad. The pharmaceutical industry will likely challenge the order legally, but Trump’s approach represents a direct response to the frustration many Americans feel about paying premium prices for essential medications.

With healthcare costs consistently ranking among voters’ top concerns, Trump’s move addresses a pain point felt across political lines. The policy’s potential for substantial cost savings resonates with conservative fiscal principles while addressing the practical financial burdens facing millions of Americans. As implementation details emerge, the true impact of this policy shift will become clearer, but it represents a rare instance where market mechanisms are being leveraged to correct what many view as an unfair pricing structure that has disadvantaged American consumers for decades.